(Q33497983)

English

Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

phase I clinical trial

0 references

multicenter clinical trial

0 references

phase II clinical trial

0 references

William Jeffery Sandborn

17

object named as

William J Sandborn

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Stephan R. Targan

2

object named as

Stephan R Targan

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Walter Reinisch

9

object named as

Walter Reinisch

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Stephen B Hanauer

7

object named as

Stephen B Hanauer

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

3

object named as

Axel U Dignass

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Daniel Baumgart

1

object named as

Daniel C Baumgart

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

10

object named as

Scott E Plevy

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Bruce A Salzberg

11

object named as

Bruce A Salzberg

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

8

object named as

Uma Mahadevan

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

15

object named as

James N Lowder

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Matthew B Frankel

16

object named as

Matthew B Frankel

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

author name string

Lloyd Mayer

4

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Gert van Assche

5

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Daan W Hommes

6

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Alan L Buchman

12

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Grigor M Mechkov

13

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Zahariy A Krastev

14

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

publication date

1 April 2010

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Inflammatory Bowel Diseases

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

620-629

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Inflammatory bowel disease: clinical aspects and established and evolving therapies

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21084

21 January 2018

Inflammatory bowel disease: cause and immunobiology

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21084

21 January 2018

European evidence-based Consensus on the management of ulcerative colitis: Current management

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21084

21 January 2018

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21084

21 January 2018

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21084

21 January 2018

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21084

21 January 2018

Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21084

21 January 2018

A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21084

21 January 2018

HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21084

21 January 2018

A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21084

21 January 2018

A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21084

21 January 2018

Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21084

21 January 2018

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21084

21 January 2018

European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21084

21 January 2018

A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21084

21 January 2018

Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21084

21 January 2018

Identifiers

10.1002/IBD.21084

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33497983&oldid=1954450767"